The trouble began after the Privy Council, the highest appellate court in Antigua and Barbuda, issued a ruling on January 16, 2025 that retroactively invalidated Sinovac’s incumbent board of directors. What followed was a wave of litigation. Sinovac and its controlling shareholders, 1Globe Capital LLC and OrbiMed Advisors LLC, filed proceedings in Antigua seeking to void Vivo’s transactions. A separate class action landed in Delaware Chancery Court, naming Vivo and one of its principals as defendants on claims of aiding and abetting shareholder oppression and unjust enrichment.